TABLE 1.
Demographic and clinicopathologic factors for all patients, dichotomized by enrollment in a clinical trial.
| All patients (n = 208) | No clinical trial (n = 163) | Clinical trial (n = 45) | p Value | |
|---|---|---|---|---|
| Age (years), median (IQR) | 58 (51–68) | 60 (51–68) | 55 (45–66) | 0.04 |
| Sex, n (%) | 0.41 | |||
| Female | 130 (63) | 99 (61) | 31 (67) | |
| Male | 78 (37) | 64 (39) | 14 (33) | |
| Race/ethnicity, n (%) | 0.02 | |||
| White | 182 (88) | 144 (89) | 38 (84) | |
| Black | 7 (3) | 2 (1) | 5 (11) | |
| Asian | 12 (6) | 10 (6) | 2 (5) | |
| Other | 6 (3) | 6 (4) | 0 (0) | |
| Insurance, n (%) | 0.84 | |||
| No insurance | 3 (2) | 2 (1) | 1 (2) | |
| Private insurance | 120 (59) | 94 (59) | 26 (61) | |
| Federally funded insurance | 80 (39) | 64 (40) | 16 (37) | |
| Education, n (%) | 0.23 | |||
| Some high school or less | 4 (2) | 2 (1) | 2 (5) | |
| Highschool graduate or equivalent | 18 (9) | 17 (10) | 1 (2) | |
| Completed some college/technical school | 42 (20) | 35 (21) | 7 (16) | |
| Associate’s degree | 19 (9) | 16 (10) | 3 (7) | |
| Bachelor’s degree | 54 (26) | 42 (26) | 12 (27) | |
| Completed some graduate school | 10 (5) | 7 (4) | 3 (7) | |
| Graduate or professional degree | 60 (29) | 44 (27) | 16 (36) | |
| Employment, n (%) | 0.52 | |||
| Unemployed | 40 (20) | 31 (19) | 9 (20) | |
| Employed | 85 (41) | 64 (40) | 21 (48) | |
| Retired | 80 (39) | 66 (41) | 14 (32) | |
| Annual income, n (%) | 0.32 | |||
| Less than $75 000 | 60 (33) | 44 (31) | 16 (39) | |
| More than $75 000 | 124 (67) | 99 (69) | 25 (61) | |
| Site of disease, n (%) | 0.50 | |||
| Intrahepatic | 156 (75) | 120 (74) | 36 (80) | |
| Extrahepatic | 52 (25) | 42 (26) | 9 (20) | |
| Stage, n (%) | 0.01 | |||
| Early stage | 96 (46) | 83 (51) | 13 (29) | |
| Locally advanced | 70 (34) | 53 (32) | 17 (38) | |
| Metastatic | 42 (20) | 27 (17) | 15 (33) | |
| Time since diagnosis (months), median (IQR) | 25 (12–48) | 23 (11–37) | 41 (16–65) | 0.06 |
| Resection, n (%) | 119 (57) | 96 (59) | 23 (51) | 0.45 |
| Neoadjuvant chemotherapy, n (%) | 42 (35) | 32 (33) | 10 (43) | 0.50 |
| Neoadjuvant radiation, n (%) | 15 (13) | 12 (13) | 3 (13) | 1.0 |
| Adjuvant chemotherapy, n (%) | 91 (77) | 72 (76) | 18 (78) | 1.0 |
| Adjuvant radiotherapy, n (%) | 46 (39) | 37 (39) | 9 (39) | 1.0 |
| Recurrence, n (%) | 57 (48) | 41 (43) | 16 (70) | 0.04 |
| Molecular profiling completed, n (%) | 167 (80) | 127 (78) | 40 (89) | 0.15 |
| Received targeted therapy, n (%) | 48 (29) | 27 (21) | 21 (53) | <0.001 |
Abbreviation: IQR, interquartile range.